FDA — authorised 12 September 2024
- Application: BLA761347
- Marketing authorisation holder: GENENTECH INC
- Local brand name: TECENTRIQ HYBREZA
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Atezolizumab and Recombinant Human Hyaluronidase in United States
FDA authorised Atezolizumab and Recombinant Human Hyaluronidase on 12 September 2024
Marketing authorisation
Other Oncology approved in United States
Frequently asked questions
Is Atezolizumab and Recombinant Human Hyaluronidase approved in United States?
Yes. FDA authorised it on 12 September 2024.
Who is the marketing authorisation holder for Atezolizumab and Recombinant Human Hyaluronidase in United States?
GENENTECH INC holds the US marketing authorisation.